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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Percutaneous transluminal angioplasty (PTA) and stenting is commonly used to treat 
subclavian artery stenosis (SAS). In this study, the outcomes of 43 consecutive cases, performed 
at one institution from October 1997 to October 2005, were analyzed. Mean stenosis was 84.41% 
pre-intervention and 6.83% post-intervention. Five of the procedures were angioplasty alone; 
38 were angioplasty with stenting. Technical success was achieved in 42 out of 43 patients. The 
30-day mortality rate was 0%. At one-month post intervention, all patients were symptom free. 
Ten patients redeveloped symptoms by one year. Demographic data, patient comorbidities, and 
indication to treat were analyzed. It was found that prior coronary intervention led to a statisti-
cally signiﬁ  cant higher rate of symptom reoccurrence (p = 0.036). Additionally, a divergence in 
the rate of symptom reoccurrence based on indication to treat SAS was noted with the highest 
rate of symptom reoccurrence in the pre-coronary artery bypass grafting (CABG) group and 
the lowest rate of symptom reoccurrence in the subclavian steal syndrome (SSS) group. The 
coronary subclavian steal (CSS) group had an intermediate rate of symptom reoccurrence. 
During this time period, 1154 CABGs were performed. Flow-limiting stenosis was noted on 
angiography in 17 of these patients, giving pre-CABG prevalence of 1.46%.
Keywords: subclavian artery stenosis, coronary steal syndrome, subclavian steal syndrome, 
coronary artery bypass graft, percutaneous intervention, restenosis
Introduction
Subclavian artery stenosis (SAS) can be treated either surgically or endovascularly. 
Long term patency rates for surgery and endovascular therapy are similar. A 10-year 
study completed in 1991 combining all extrathoracic surgical techniques documented 
patency rates of 95% at one year, 86% at three years, and 73% at ﬁ  ve years (Salam 
1994). A 10-year, single-center study completed in 2005 documented an initial techni-
cal success rate of 93% and a ﬁ  ve-year clinical patency rate of 89% with percutaneous 
transluminal angioplasty (PTA) (De Vries 2005). A 1999 comparison study between 
stenting and surgical treatment of subclavian and brachiocephalic artery stenosis 
demonstrated equal effectiveness but fewer complications in the stenting group; it 
concluded that stenting should be ﬁ  rst line therapy for subclavian or brachiocephalic 
obstruction (Hadjipetrou 1999).
Subclavian artery stenosis can lead to a myriad of symptoms depending on the 
underlying pathology and anatomy. In patients who have undergone CABG using the 
left internal mammary artery (LIMA), the subclavian artery functionally becomes part 
of the coronary circulation via the LIMA (Elian 2002). Ischemia distal to a stenotic 
subclavian artery in this clinical picture can lead to angina; this deﬁ  nes the coronary Vascular Health and Risk Management 2006:2(4) 465–475
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steal syndrome. Given the potential complications of CSS, 
every effort to detect SAS before using a LIMA graft should 
be made (Harjola 1974). At the institution studied, subclavian 
arteriography is routinely performed at cardiac catheteriza-
tion in patients who will likely require CABG.
While safety and efﬁ  cacy of endovascular therapy in SAS 
has been fairly well established, the low prevalence means 
these patients remain a unique population that most inter-
ventionalists see only occasionally. The prevalence of SAS 
is 3.5% in the general population and 5.3% in patients with 
potential surgical coronary disease (English 2001). Therefore, 
more data are needed to assess what clinical picture will lead 
to higher rates of symptom reoccurrence in this unique patient 
population. Also, more published data are necessary to accu-
rately determine the prevalence at SAS prior to CABG.
Methods
The subject population consisted of 43 consecutive patients 
with subclavian or brachiocephalic artery stenosis or occlu-
sion, who underwent PTA or stenting between Oct. 1997 and 
Oct. 2005 at a large military medical treatment facility (MTF) 
in southern California. All patients were included; there was 
no exclusion criterion. Follow-up data were obtained from 
inpatient records, outpatient clinic notes, and more recently 
from the electronic medical record.
Patient demographics, patient comorbidities, and indica-
tion to perform the procedure were analyzed to ascertain if the 
variable in question led to a statistically signiﬁ  cant difference 
in symptom reoccurrence at 12 months.
The pre-CABG group was defined as patients with 
angiographic evidence of SAS and a planned LIMA graft to 
the left anterior descending artery (LAD). The CSS group 
was deﬁ  ned as angina in a patient with a LIMA graft and 
ﬂ  ow-limiting SAS. The SSS group was deﬁ  ned by both arm 
claudication or vertebrobasilar symptoms and SAS. Symp-
tom reoccurrence was deﬁ  ned as return of the above-noted 
symptoms. Symptoms were evaluated either in the clinic 
or in the hospital. Complete information at 12 months 
was obtained in all patients.
Statistical analysis was performed by the statistics depart-
ment at the MTF. Analysis using Fisher’s Least Signiﬁ  cant 
Difference test was performed. p values  0.05 were consid-
ered statistically signiﬁ  cant.
An institutional review board approved the study.
Results (see Tables 1–3)
Thirty-eight of the 43 patients were treated with PTA and 
stent; ﬁ  ve were treated with angioplasty alone. Thirty-nine 
of the total lesions were located in the left subclavian artery, 
with two of these lesions distal to the vertebral artery. One 
lesion was located in the right subclavian artery, and three 
were located in the brachiocephalic artery. Technical suc-
cess was achieved in 42 out of the 43 patients (97.67%). 
The patient with technical failure had a total occlusion, 
and the guide wire could not be passed despite femoral and 
brachial approaches. The patient was referred to vascular 
surgery. Mean stenosis pre-intervention was 84.41% (range 
60%–100%), with three total occlusions. Mean stenosis post-
intervention was 6.83% (range 0%–30%).
The 30-day mortality was 0%; all patients were also 
symptom free at this point. Two patients developed symp-
toms two months after the procedure. Seven patients devel-
oped symptoms six months after the procedure, and 10 
developed symptoms one year after the procedure.
The mean patient age was 67.6 years; 48.8% of the 
patients were male, 90.7% had hypertension, 46.5% had 
diabetes, and 88.4% were being treated for hyperlipidemia. 
Obesity (BMI   30) was present in 32.6% of the patients; 
60.5% of the patients were smokers, 95.3% had coronary 
artery disease, 48.8% had a previous myocardial infarct, 
and 55.8% had either a previous CABG or Percutaneous 
Coronary Intervention (PCI).
Of the demographic data analyzed, only one group was 
shown to have an increased risk of symptom reoccurrence: 
patients who had had a previous PCI or CABG (p = 0.036). 
When this group was further subdivided, it was noted that 
those undergoing the procedure for pre-CABG screening 
were at increased risk for developing symptoms (p = 0.025). 
Patients undergoing the procedure for subclavian steal 
or coronary steal were not at increased risk for symptom 
redevelopment.
Seventeen (39.5%) of the 43 patients treated met pre-
CABG criteria. Thirteen (30.2%) patients treated met the 
Table 1 Clinical characteristics of the study group (N = 43)
Demographics #  Percent  p
Men 21  48.8%  0.419 
Hypertension 39  90.7%  0.649
Diabetes Mellitus  20  46.5%  0.246
Hyperlipidemia 38  88.4%  0.212
Obesity (BMI   30) 14 32.6%  0.066
Smoking 26  60.5%  0.581
CAD 41  95.3%  0.479
Previous MI  21  48.8%  0.168
Previous PTCA/CABG  24  55.8%  0.036
History of previous PTCA/CABG was a clinical characteristic that signiﬁ  cantly 
predisposed to symptom reoccurrence at 12 months.Vascular Health and Risk Management 2006:2(4) 465–475
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Symptom reoccurrence after endovascular therapy in subclavian artery stenosis
CSS criteria. Twelve (27.9%) patients met the SSS criteria. 
One (2.3%) patient did not ﬁ  t into one of the above catego-
ries; the procedure indication for this patient was iatrogenic 
dissection during diagnostic catheterization.
There was divergence of the data based on indication to 
intervene with the pre-CABG group experiencing the highest 
rates of reoccurrence (35.3%) at 12 months followed by the 
CSS group (23.1%) and the SSS group (8.3%).
Eleven hundred and ﬁ  fty-four CABG procedures were 
performed during the study period. All patients had had angi-
ographies prior to the procedure, and the subclavian artery 
was routinely evaluated for stenosis. Seventeen (1.47%) of 
the pre-CABG patients had signiﬁ  cant SAS that required 
PTA or stenting.
Discussion
This retrospective study of 43 consecutive patients with ﬂ  ow-
limiting SAS again illustrates that percutaneous intervention 
is safe, with a 30-day mortality rate of 0%, and effective, 
with technical success achieved in 97.67% of patients. The 
primary success rate of  90% in this study was consistent 
with other larger studies (Henry 1999; Amor 2004).
Assessing the clinical picture that leads to the highest rate 
of symptom reoccurrence is useful information to help deter-
mine how closely to follow a patient post-intervention. In this 
study, there was a higher incidence of symptom reoccurrence 
in patients who had a history of prior coronary intervention. 
This seems somewhat intuitive, as patients with prior coronary 
intervention would have the most widespread and advanced 
atherosclerosis. Following this logic, there was also a diver-
gence of the data regarding indication for intervention, with 
pre-CABG and CSS patients experiencing higher rates of 
symptom reoccurrence compared with SSS patients.
The prevalence of ﬂ  ow-limiting and overall stenosis of 
the subclavian artery in patients undergoing CABG is not 
well known. In our population, the prevalence was 1.47%. 
This appears to be lower than the 3.4% incidence of CSS 
documented in a recent prospective study of non-cardiac 
surgery patients (Lobato 2001). Studies report the prevalence 
of SAS in patients undergoing CABG ranges from 0.5% to 
1.1% (Westerband 2003). Larger studies and meta-analysis 
are needed to more precisely determine the prevalence of 
SAS in patients going to CABG. Another potential avenue 
of research is determining if PTA or stenting in patients with 
ﬂ  ow-limiting SAS and planned LIMA graft protect the patient 
from developing CSS.
Limitations to this study include: (1) it is retrospective, 
(2) it has low power, (3) there was heterogeneity in the pro-
cedures performed, and (4) a rather subjective endpoint was 
used. Given that angiographic evidence of restenosis was 
not assessed, symptom reoccurrence may have been due to 
progression of CAD or graft stenosis in CABG patients and 
not restenosis of the left subclavian artery. Indeed, a recent 
study concluded that progression of CAD rather than recur-
rent SAS most often leads to coronary symptoms after left 
subclavian artery percutaneous intervention (Angle 2003). 
In the BARI study (Whitlow 1999), 12% of patients had 
reoccurrence of angina 12 months after CABG. Repeat angi-
ography was performed on all patients with 20% of patients 
having greater than 1 totally occluded graft and an additional 
7% of patients having graft stenosis of 50%–99%.
Conclusion
The current study once more illustrates that endovascular 
therapy in SAS is safe and can be performed with a high 
Table 2 Procedural data and results (N = 43)
Procedure n  Percent
Mean stenosis   
 Pre-intervention  (60%–100%)  84.40%
 Post-intervention  (0%–30%)  6.80%
Balloon angioplasty  5  11.60%
Stent placement  38  88.40%
Stenosis 40  93.00%
Total occlusion  3  7.00%
Technical success  42  97.67%
30-day mortality  0  0.00%
Table 3 Symptoms reoccurrence
 n  %
All interventions (n = 43)
 1  month  0  0
 2  months  2  4.6
 6  months  7  16.2
 12  months  10  23.3
Pre-CABG (n = 17)
 1  month  0  0
 2  months  1  5.9
 6  months  4  23.6
 12  months  6  35.3
Subclavian steal syndrome (n = 12)
 1  month  0  0
 2  months  0  0
 6  months  1  8.3
 12  months  1  8.3
Coronary steal syndrome (n = 13)
 1  month  0  0
 2  months  1  7.7
 6  months  2  15.4
 12  months  3  23.1Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
Coronary artery disease in women: a review
on prevention, pathophysiology, diagnosis, and
treatment
A
u
t
h
o
r
 
c
o
p
y
 
o
n
l
y
Vascular Health and Risk Management 2007:3(5) 762
Van Noord et al
level of initial technical success. A 30-day mortality rate of 
0% and an initial success in over 95% of patients were noted. 
A statistically signiﬁ  cant higher rate of symptom reoccur-
rence was seen with a history of prior coronary intervention. 
There was a divergence in the rates of symptom reoccurrence 
based on indication, with the pre-CABG and CSS groups 
experiencing higher rates of symptom return compared with 
the SSS group. The higher rate of symptom reoccurrence 
in patients with coronary disease requires a close post-
intervention follow-up after treatment of SAS. Finally, 
the prevalence of SAS in patients undergoing CABG is low 
at less than 2%.
Note
The Chief, Bureau of Medicine and Surgery, Navy Depart-
ment, Washington, D.C., Clinical Investigation Program, 
sponsored this report CIP #S-06-016 as required by NSHS-
BETHINST 6000.41B. The views expressed in this article 
are those of the authors and do not reﬂ  ect the ofﬁ  cial policy 
or position of the Department of the Navy, Department of 
Defense, or the United States Government.
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